Cargando…
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
BACKGROUND: A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical...
Autores principales: | Furtado, Remo H. M., Venkateswaran, Ramkumar V., Nicolau, Jose C., Gurmu, Yared, Bhatt, Deepak L., Storey, Robert F., Steg, P. Gabriel, Magnani, Giuglia, Goto, Shinya, Dellborg, Mikael, Kamensky, Gabriel, Isaza, Daniel, Aylward, Philip, Johanson, Per, Bonaca, Marc P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660882/ https://www.ncbi.nlm.nih.gov/pubmed/32410485 http://dx.doi.org/10.1161/JAHA.119.015785 |
Ejemplares similares
-
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018) -
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021) -
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019) -
Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial
por: Gencer, Baris, et al.
Publicado: (2020) -
Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)